Enrollment of Older Persons in Cancer Trials After the Medicare Reimbursement Policy Change
Archives of Internal MedicinePublished 11 July 2005Open access
Cary P. Gross, Natalie Wong, Joel A. Dubin, Susan T. Mayne, Harlan M. Krumholz
Citations30
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The Medicare trial reimbursement policy was not associated with a significant increase in the enrollment of older patients in cancer trials.
Abstract
The Medicare trial reimbursement policy was not associated with a significant increase in the enrollment of older patients in cancer trials.
Keywords
MedicineEconomics, Econometrics and Finance
RePEc: Research Papers in EconomicsEconometric Analysis of Cross Section and Panel Data
28,336 Citations2001Jeffrey M. Wooldridge
American Journal of Clinical OncologyToxicity and response criteria of the Eastern Cooperative Oncology Group
11,623 Citations1982Martin M. Oken, Richard H. Creech +5 more
The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
BiometricsA Note on Robust Variance Estimation for Cluster‐Correlated Data
2,523 Citations2000Rick L. Williams
This brief note presents a general proof that the estimator is unbiased for cluster-correlated data regardless of the setting.
New England Journal of MedicineUnderrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
2,177 Citations1999Laura F. Hutchins, Joseph M. Unger +3 more
There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.
JAMAParticipation in Cancer Clinical Trials
2,044 Citations2004Vivek H. Murthy, Harlan M. Krumholz +1 more
Although the total number of trial participants increased during the study period, the representation of racial and ethnic minorities decreased and were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively.
Journal of Clinical OncologyKarnofsky performance status revisited: reliability, validity, and guidelines.
1,507 Citations1984Cyndie Coscarelli Schag, Richard Heinrich +1 more
Oncologists may train themselves to use the Karnofsky Performance Status in a standard way, which should increase reliability and validity of the KPS and has implications for patients and research studies that use KPS as a stratifying variable.
Journal of Clinical OncologyParticipation of Patients 65 Years of Age or Older in Cancer Clinical Trials
1,043 Citations2003Joy H. Lewis, Meredith L. Kilgore +6 more
The elderly are underrepresented in cancer clinical trials relative to their disease burden, and older patients are more likely to have medical histories that make them ineligible for clinical trials because of protocol exclusions.
Journal of Clinical OncologyBarriers to Clinical Trial Participation by Older Women With Breast Cancer
467 Citations2003Margaret Kemeny, Bercedis L. Peterson +7 more
Age and stage were the only predictors of whether a patient was offered a trial in a multivariate analysis including comorbid conditions, and the physicians' perceptions about age and tolerance of toxicity were the greatest impediment to enrolling older women onto trials.
Journal of Clinical OncologyRandomized Clinical Trials in Oncology: Understanding and Attitudes Predict Willingness to Participate
248 Citations2001Peter M. Ellis, Phyllis Butow +3 more
It is suggested that women who have a better understanding of issues about clinical trials have more favorable attitudes toward randomized trials and are more willing to consider participation in a clinical trial.
Journal of Clinical OncologyOncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study.
248 Citations1991Al B. Benson, Janet Pregler +4 more
CancerThe impact of socioeconomic status and race on trial participation for older women with breast cancer
173 Citations2004Cary P. Gross, Giovanni Filardo +2 more
Older women, and older minorities in particular, are under represented in breast cancer trials, and socioeconomic status (SES) is associated with both race and age.
Archives of Internal MedicineLying for Patients
162 Citations1999Vera Freeman, Saif S. Rathore +3 more
Ratings of the justifiability of deception varied by perspective and vignette, and rates were highest for physicians practicing in predominantly managed care markets, for clinically severe vignettes, and for physicians spending less time in clinical practice.
University Libraries (University of Maryland)Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
107 Citations2004Murthy, Vivek H., Krumholz, Harlan M. +1 more
Southern Medical JournalFactors Influencing Enrollment in Clinical Trials for Cancer Treatment
99 Citations1999C. Klabunde, Bethesda +6 more
Although multiple factors influence enrollment in clinical trials for cancer treatment, results suggest that insurance coverage plays a role and points to the need for continued efforts to educate physicians and the public in the value of clinical trials.
Journal of Clinical EpidemiologyInfluence of race, clinical, and other socio-demographic features on trial participation
74 Citations2003Giselle Corbie‐Smith
Conditions associated with the intervention, such as a history of hysterectomy or previous estrogen replacement use, were strongly associated with a woman's decision to participate in this clinical trial.
Archives of Internal MedicineEffect of Medicare Coverage on Use of Invasive Colorectal Cancer Screening Tests
66 Citations2002Cynthia W. Ko, William Kreuter +1 more
Colorectal cancer screening tests are underused in the Washington State Medicare population, and insurance coverage for these tests did not substantially affect utilization rates in the period studied.
JNCI Journal of the National Cancer InstituteCancer Trial Enrollment After State-Mandated Reimbursement
40 Citations2004Cary P. Gross, Vivek Murthy +3 more
State coverage policies were associated with a statistically significant increase in phase II cancer trial participation and did not increase phase III cancer trial enrollment.
Archives of Internal MedicineThe "Hassle Factor"
38 Citations2002Rachel M. Werner, G. Caleb Alexander +2 more
Physicians are more willing to sanction deception when the appeals process is longer, the likelihood of a successful appeal is lower, and the health condition is more severe.
RadiologyEffect of a legislative mandate on mammography use and coding practices in Maryland.
12 Citations1996Peter E. Dans, A T Wright
The number of mammograms obtained increased only modestly after the mandate, but claims coded for mammography bilateral declined dramatically, and removal of financial barriers appears to be insufficient to increase appropriate use of screening mammography.
CancerDissemination of information on legislative mandates and consensus‐based programs addressing payment of the costs of routine care in clinical trials through the World Wide Web
10 Citations2004Andrew M. Kelahan
To eliminate the potential for denial of payment by a health plan that can act as a barrier to participation, the public must be aware that these programs exist and what they entail.
JNCI Journal of the National Cancer InstituteThird-Party Reimbursement Issues During a Phase 1 Trial of Interleukin-2
7 Citations1989N. J. Vogelzang, Josh Richards
The Journal of UrologyCancer Trial Enrollment After State-Mandated Reimbursement
3 Citations2005Cary P. Gross, Vivek Murthy +3 more
The Journal of Law Medicine & EthicsMedicare: Coverage Approved for Participation in Clinical Trials
2 Citations2000Jodie A. Hamill
CancerDissemination of information on legislative mandates and consensus‐based programs addressing payment of the costs of routine care in clinical trials through the World Wide Web
1 Citations2004Valerie Monaco
Optimal performance in screening mammography should be evaluated quantitatively and the general pressure to reduce recall rates through “practice guidelines” to below a fixed level for all radiologists should be assessed carefully.